These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

737 related articles for article (PubMed ID: 8656505)

  • 1. Economic impact of treatment of HIV-positive pregnant women and their newborns with zidovudine. Implications for HIV screening.
    Mauskopf JA; Paul JE; Wichman DS; White AD; Tilson HH
    JAMA; 1996 Jul; 276(2):132-8. PubMed ID: 8656505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of short-course zidovudine to prevent perinatal HIV type 1 infection in a sub-Saharan African Developing country setting.
    Mansergh G; Haddix AC; Steketee RW; Nieburg PI; Hu DJ; Simonds RJ; Rogers M
    JAMA; 1996 Jul; 276(2):139-45. PubMed ID: 8656506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preventing perinatal transmission of HIV--costs and effectiveness of a recommended intervention.
    Gorsky RD; Farnham PG; Straus WL; Caldwell B; Holtgrave DR; Simonds RJ; Rogers MF; Guinan ME
    Public Health Rep; 1996; 111(4):335-41. PubMed ID: 8711101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of universal compared with voluntary screening for human immunodeficiency virus among pregnant women in Chicago.
    Immergluck LC; Cull WL; Schwartz A; Elstein AS
    Pediatrics; 2000 Apr; 105(4):E54. PubMed ID: 10742375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV infection and zidovudine use in childbearing women.
    Sia J; Paul S; Martin RM; Cross H
    Pediatrics; 2004 Dec; 114(6):e707-12. PubMed ID: 15545619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Universal HIV screening of pregnant women in England: cost effectiveness analysis.
    Postma MJ; Beck EJ; Mandalia S; Sherr L; Walters MD; Houweling H; Jager JC
    BMJ; 1999 Jun; 318(7199):1656-60. PubMed ID: 10373167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of mandatory compared with voluntary screening for human immunodeficiency virus in pregnancy.
    Myers ER; Thompson JW; Simpson K
    Obstet Gynecol; 1998 Feb; 91(2):174-81. PubMed ID: 9469271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of strategies to reduce mother-to-child HIV transmission in Mexico, a low-prevalence setting.
    Rely K; Bertozzi SM; Avila-Figueroa C; Guijarro MT
    Health Policy Plan; 2003 Sep; 18(3):290-8. PubMed ID: 12917270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The reduction of mother-child transmission of HIV infection in developing countries: potential intervention strategies, obstacles to implementation and perspectives. The Reduction of Mother-Child Transmission of HIV Infection in Africa Group].
    Meda N; Msellati P; Welffens-Ekra C; Cartoux M; Leroy V; Van de Perre P; Salamon R
    Sante; 1997; 7(2):115-25. PubMed ID: 9273118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of antiviral drug therapy to reduce mother-to-child HIV transmission in sub-Saharan Africa.
    Marseille E; Kahn JG; Saba J
    AIDS; 1998 May; 12(8):939-48. PubMed ID: 9631148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of interventions to reduce vertical HIV transmission from pregnant women who have not received prenatal care.
    Mrus JM; Tsevat J
    Med Decis Making; 2004; 24(1):30-9. PubMed ID: 15005952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost-effectiveness of voluntary intrapartum rapid human immunodeficiency virus testing for women without adequate prenatal care.
    Grobman WA; Garcia PM
    Am J Obstet Gynecol; 1999 Nov; 181(5 Pt 1):1062-71. PubMed ID: 10561619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The costing of HIV/AIDS--without a clue?
    van der Linde I
    S Afr Med J; 1999 Jan; 89(1):33-4. PubMed ID: 10070404
    [No Abstract]   [Full Text] [Related]  

  • 14. Perinatal HIV infection and the effect of zidovudine therapy on transmission in rural and urban counties.
    Fiscus SA; Adimora AA; Schoenbach VJ; Lim W; McKinney R; Rupar D; Kenny J; Woods C; Wilfert C
    JAMA; 1996 May; 275(19):1483-8. PubMed ID: 8622222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid testing and zidovudine treatment to prevent vertical transmission of human immunodeficiency virus in unregistered parturients: a cost-effectiveness analysis.
    Stringer JS; Rouse DJ
    Obstet Gynecol; 1999 Jul; 94(1):34-40. PubMed ID: 10389714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pediatric HIV disease, zidovudine in pregnancy, and unblinding heelstick surveys. Reframing the debate on prenatal HIV testing.
    Minkoff H; Willoughby A
    JAMA; 1995 Oct; 274(14):1165-8. PubMed ID: 7563489
    [No Abstract]   [Full Text] [Related]  

  • 17. National and provincial estimated costs and cost effectiveness of a programme to reduce mother-to-child HIV transmission in South Africa.
    Wilkinson D; Floyd K; Gilks CF
    S Afr Med J; 2000 Aug; 90(8):794-8. PubMed ID: 11022629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incremental cost-effectiveness of two zidovudine regimens to prevent perinatal HIV transmission in the United States.
    Pinkerton SD; Holtgrave DR; Layde PM
    Prev Med; 2000 Jan; 30(1):64-9. PubMed ID: 10642461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Costs and benefits of screening pregnant women for HIV.
    Bueckert H
    CMAJ; 1996 Nov; 155(10):1387. PubMed ID: 8943920
    [No Abstract]   [Full Text] [Related]  

  • 20. Zidovudine use to reduce perinatal HIV type 1 transmission in an urban medical center.
    Wiznia AA; Crane M; Lambert G; Sansary J; Harris A; Solomon L
    JAMA; 1996 May; 275(19):1504-6. PubMed ID: 8622226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.